Usage of New Anti-cancer Drugs in Nanjing from 2018 to 2020

doi:10.19803/j.1672-8629.2021.08.06

Abstract

Abstract: Objective To analyze the data on procurement of new anti-cancer drugs in Nanjing between 2018 and 2020 and find out about the recent usage of such drugs and developments in order to provide reference for clinical rational use of new anti-cancer drugs and national medical insurance admittance. Methods Based on the procurement data by Jiangsu Institute of Medical Information in Nanjing from 2018 to 2020, the DDDs, consumption amount, defined daily dose cost (DDDc) and B/A value were retrospectively analyzed. Results The consumption amount and constituent ratio of new anti-cancer drugs continued to rise. DDDs increased rapidly, the DDDs of PD1 drugs increased significantly, but DDDc of most of these drugs continued downward. The DDDc of most monoclonal antibody drugs was high. The B/A values of most drugs were elevated while drug synchronization improved. Conclusion The usage of new anti-cancer drugs is on the increase, and these drugs are entering the medical insurance directory one after another. The availability and affordability of new anti-cancer drugs have been significantly improved. These drugs are being used more rationally.

Key words: anti-cancer drugs, drug usage, DDDs, consumption amount, DDDc, medical insurance directory

CLC Number:

R979.1 R73

HE Xuan, WANG Xiao, DAI Huizhen, LI Xin, HAN Feng. Usage of New Anti-cancer Drugs in Nanjing from 2018 to 2020[J]. Chinese Journal of Pharmacovigilance, 2021, 18(8): 725-730.

References

[1] WHO. Global Health Estimates(GHE)[EB/OL]. (2020-12-08)[2021-03-19]. https://www.who.int/healthinfo/global_burden_disease/en/.
[2] Zou XN, Jia MM, Wang X, et al.Interpretation of the World Cancer Report 2020[J]. Chinese Journal of Clinical Thoracic and Cardiova-scular Surgery(中国胸心血管外科临床杂志), 2021, 28(1): 11-18.
[3] Wang YJ, Wang N.Types of tumor molecular targeted therapies and mechanisms of action[J]. Chinese Journal of Practical Surgery(中国实用外科杂志), 2010, 30(7): 526-529.
[4] Zhou YP, Wang HG, Hu QH, et al.Accessibility of high-cost anti-cancer medicines in China[J]. Chinese Journal of Evidence-Based Medicine(中国循证医学杂志), 2017,17(7): 862-868.
[5] National Healthcare Security Administration. National Healthcare Security Administration Ministry of Human Resources and Social Security Notice on Issuing the《National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List(2020)》[EB/OL].(2020-12-28) [2021-03-19]. http://www.nhsa.gov.cn/art/2020/12/28/art_37_4220.html.
[6] National Healthcare Security Administration. Notice on the inclusion of 17 anti-cancer drugs into the category B scope of the national basic medical insurance, work injury insurance and maternity insurance drug catalog[EB/OL]. (2018-10-10) [2021-03-19]. http://www.nhsa.gov.cn/art/2018/10/10/art_37_1057.html.
[7] Ye JD, Yu KF, Zhu P, et al.Classification and research progress of targeted anti-tumor drugs[J]. Progress in Pharmaceutical Sciences(药学进展), 2018, 42(5): 351-358.
[8] National Health Commission. Notice of the General Office of the National Health Commission on Issuing the Guidelines for the Clinical Application of New Anti-tumor Drugs (2020 Edition) [EB/OL]. (2020-12-29) [2021-03-19]. http://www.nhc.gov.cn/yzygj/s7659/202012/6c00e8559ee54cd29585c7f39e8a23c4.shtml.
[9] Fang WQ, Xu XL, Dai HZ, et al.Influence of national medical insurance admittance negotiated policy on the utilization of innova-tive anticancer drugs[J]. Herald of Medicine(医药导报), 2020, 39(12): 1665-1672.
[10] Song GH, Li HP, Qiu LJ, et al.Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: realworld practice[J]. Journal of Peking University(Health Sciences)(北京大学学报(医学版)), 2020, 52(2): 254-260.
[11] Guo L.Comparison of clinical effects of gefitinib and icotinib in targeted treatment of advanced non-small cell lung cancer[J]. Journal of Medical Theory and Practice(医学理论与实践), 2021, 34(5): 794-795.
[12] Zhao DL, Ma J.Progress in the clinical treatment of chronic lymphocytic leukemia[J]. Journal of Internal Medicine Concepts & Practice(内科理论与实践), 2020, 15(5): 290-294.
[13] Burger JA, Tedeschi A, Barr PM, et al.Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia[J]. N Engl J Med, 2015, 373(25): 2425-2437.
[14] Woyach JA, Ruppert AS, Heerema NA, et al.Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL[J]. N Engl J Med, 2018, 379(26): 2517-2528.
[15] Fang WT, Luo C, Dai HZ, et al.Applicationanalysis and medicare payments prediction of new selected anti-tumor drugs of medical insurance in Nanjing City[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2018, 38(11): 1131-1137.
[16] Xu WQ, Li Y.Discussion on the strategy of hospital medication management based on the changes of medical insurance drug catalogue in 2019[J]. Chinese Pharmaceutical Affairs(中国药事), 2020, 34(10): 1209-1213.